SCHEMBL3222007

SCHEMBL3222007

CNCC(=O)NC[C@H](Cc1ccc(-c2cn(C)c(C(C)(C)O)n2)cc1)NC(=O)c1ccc(O[C@H](C)C(F)(F)F)c(Cl)c1

nearest known ligand 0.49

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
CENPE Q02224 3/20 0.49
DHODH Q02127 8/20 0.43
KIFC1 Q9BW19 1/20 0.37
RORC P51449 1/20 0.33
PDK1 Q15118 1/20 0.33
PDK2 Q15119 1/20 0.33
PDK3 Q15120 1/20 0.33
PDK4 Q16654 1/20 0.33
TAS1R3 Q7RTX0 1/20 0.32
TAS1R1 Q7RTX1 1/20 0.32
P2RX3 P56373 2/20 0.31
MME P08473 2/20 0.30
MRGPRX4 Q96LA9 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3222019 1.00 CENPE (0.49) CENPEDHODHKIFC1RORCPDK1
SCHEMBL3229432 0.93 CENPE (0.49) CENPEDHODHKIFC1RORCPDK1
SCHEMBL3229438 0.93 CENPE (0.49) CENPEDHODHKIFC1RORCPDK1
SCHEMBL3217093 0.93 CENPE (0.50) CENPEDHODHKIFC1RORCPDK1
SCHEMBL3217081 0.93 CENPE (0.50) CENPEDHODHKIFC1RORCPDK1
SCHEMBL3220750 0.91 CENPE (0.60) CENPEDHODHKIFC1RORCPDK1
SCHEMBL3220765 0.91 CENPE (0.60) CENPEDHODHKIFC1RORCPDK1
SCHEMBL3220019 0.91 CENPE (0.48) CENPEDHODHKIFC1PDK1PDK2
SCHEMBL3220035 0.91 CENPE (0.48) CENPEDHODHKIFC1PDK1PDK2
SCHEMBL3220603 0.90 CENPE (0.50) CENPEDHODHKIFC1RORCPDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100069453-A1 Certain Chemical Entities, Compositions, and Methods CYTOKINETICS, INC. 2010-03-18 US claimed
EP-1951719-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-08-06 EP claimed
US-20070149516-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-28 US claimed
WO-2007056469-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO claimed
US-20100069453-A1 Certain Chemical Entities, Compositions, and Methods CYTOKINETICS, INC. 2010-03-18 US disclosed
US-7582668-B2 Imidazoyl-benzamide anti-cancer agents CYTOKINETICS, INCORPORATED (US) 2009-09-01 US disclosed
EP-1951719-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-08-06 EP disclosed
US-20070149516-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-28 US disclosed
WO-2007056469-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069453-A1 Certain Chemical Entities, Compositions, and Methods KIF5B, KIF2C, PLK1 CENPE 54/4885DHODH 1141/4885KIFC1 4/4885
US-20070149516-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 CENPE 54/4885DHODH 1141/4885KIFC1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.